Announced
Completed
Financials
Tags
Cross Border
Private Equity
Private
Completed
China
Friendly
medical devices
Minority
Single Bidder
Acquisition
Medical Equipment
Synopsis
Goldman Sachs Asset Management, a private equity arm of Goldman Sachs, led a Series B financing round in Puyi Biotechnology, a provider of high-value medical devices. Financial terms were not disclosed. "We are impressed by the Puyi Biotechnology team and their strong bioengineering capability. The company's CRS implant is a first-to-market product targeting patients in China, many of whom experience deteriorating conditions as a result of physiological and environmental factors. In addition, the company has transplanted its core competency to serve the field of gynecology. Puyi Biotechnology's intrauterine implant device is a potential first-in-class product to treat intrauterine adhesion – a leading cause of infertility globally. We are excited by the prospects of the company's product portfolio in raising the standard of care and look forward to helping Puyi grow its ecosystem," said Kevin Xu, Goldman Sachs Asset Management Managing Director.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.